Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

L-NAME

L-NAME inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.

Product Specifications

CAS Number

50903-99-6

Product Name Alternative

NG-Nitroarginine methyl ester

UNSPSC

12352211

Hazard Statement

H315-H319-H320

Target

NO Synthase

Related Pathways

Immunology/Inflammation

Field of Research

Cancer

Smiles

N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O

Molecular Formula

C7H15N5O4

Molecular Weight

233.23

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME) : requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118 (6) :1433-40.|[2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64 (3) :511-20.|[3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11 (3) :e0151973.|[4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8.|[5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64 (6) :727-36.|[6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3.|[7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5.|[8]de Alwis N, et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci Alliance. 2022 Aug 5;5 (12) :e202201517.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Phase 2

Citation 01

Biomed Pharmacother. 2020 Aug;128:110240.|Cell Tissue Res. 2022 Apr;388 (1) :181-194.|Adv Sci (Weinh) . 2024 Jun;11 (21) :e2309002.|Aging Cell. 2025 Feb 6:e14502.|Aging Cell. 2025 Sep 29:e70222.|Am J Physiol Cell Physiol. 2025 Oct 30.|Arterioscler Thromb Vasc Biol. 2020 Jul;40 (7) :1705-1721.|Bioengineered. 2022 Jan;13 (1) :1320-1334.|Biol Direct. 2024 Nov 26;19 (1) :121.|Biomed Pharmacother. 2019 Jul:115:108934.|Biomed Pharmacother. 2023 May:161:114484.|Biomed Res Int. 2021 May 14:2021:5565748.|bioRxiv. 2023 Dec 4.|bioRxiv. 2023 Nov 1.|bioRxiv. 2025 May 06.|BMC Nephrol. 2024 Jul 15;25 (1) :226.|Bosn J Basic Med Sci. 2017 May 20;17 (2) :132-137.|Brain Dev. 2025 Jul 1;47 (4) :104388.|Cancer Metab. 2024 May 17;12 (1) :14.|Cancer Res. 2024 Jun 14;84 (12) :1963-1977.|Cardiovasc Diabetol. 2024 May 9;23 (1) :164.|Cell Commun Signal. 2021 Mar 18;19 (1) :35.|Chem Biol Interact. 2025 May 28:111577.|Clin Epigenetics. 2025 Nov 19;17 (1) :195.|Clin Exp Pharmacol Physiol. 2025 Nov;52 (11) :e70081.|Commun Biol. 2025 Nov 25;8 (1) :1682.|Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641.|Exp Anim. 2025 Oct 30.|Exp Ther Med. 2018 Aug;16 (2) :1079-1086.|FASEB J. 2024 Jul 31;38 (14) :e23844.|FASEB J. 2025 Jul 31;39 (14) :e70817.|FASEB J. 2025 Jun 15;39 (11) :e70697.|Free Radic Biol Med. 2024 Sep 13:S0891-5849 (24) 00659-2.|Free Radic Biol Med. 2025 Jul:234:72-85.|Front Cardiovasc Med. 2021 Apr 13:8:654254.|Front Med. 2021 Apr 13:8:634882.|Hum Gene Ther. 2023 Jan;34 (1-2) :42-55.|Insect Mol Biol. 2024 Jun;33 (3) :206-217.|Int Immunopharmacol. 2024 Jan 25:127:111313.|Int Immunopharmacol. 2024 Nov 13;143 (Pt 3) :113617.|Int J Immunopathol Pharmacol. 2022 Jan-Dec:36:3946320221111117.|Int J Med Sci. 2025 Jan 21;22 (4) :920-932. |Int J Mol Med. 2024 Aug;54 (2) :67.|Int J Mol Sci. 2023 Mar 7;24 (6) :5111.|J Cardiovasc Transl Res. 2024 Dec;17 (6) :1415-1426.|J Cell Mol Med. 2024 Apr;28 (8) :1-11.|J Ethnopharmacol. 2022 Oct 5:296:115476.|J Extracell Vesicles. 2023 May;12 (5) :e12328.|J Nanobiotechnology. 2025 Aug 26;23 (1) :590.|JCI Insight. 2021 Sep 22;6 (18) :e133690.|Mediators Inflamm. 2019 Oct 7;2019:6168340.|Mediators Inflamm. 2020 Oct 24;2020:1649453.|Microorganisms. 2024 Dec 2;12 (12) :2483.|Microvasc Res. 2023 Jul:148:104531.|Mol Cell Probes. 2023 Feb:67:101896.|Nutrients. 2022 Nov 25;14 (23) :5025.|PeerJ. 2023 May 25:11:e15407.|Peptides. 2024 Dec 5:183:171333.|Phytomedicine. 2022 Sep:104:154242.|Placenta. 2021 Mar:106:30-39.|Placenta. 2022 Jan:117:95-108.|Res Sq. 2025 Nov 12.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 May 30.|Sci Rep. 2025 Oct 31;15 (1) :38208.|Sex Med. 2025 Aug 6;13 (4) :qfaf059.|Signal Transduct Target Ther. 2025 May 28;10 (1) :167.|Toxicol Appl Pharmacol. 2019 Mar 1:366:83-95.|University of Jena. 2023 Dec.|Vet Microbiol. 2022 Sep:272:109514.

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

CRMP2 Rabbit Polyclonal Antibody (Cy3)
orb988109 100 µL

CRMP2 Rabbit Polyclonal Antibody (Cy3)

Sign In for Pricing
View Details
NLRP5 (C-terminus) Immunizing Peptide
orb737608 100 µg

NLRP5 (C-terminus) Immunizing Peptide

Sign In for Pricing
View Details
Rbbp7 AAV Vector (Rat) (CMV)
38579106 1 µg

Rbbp7 AAV Vector (Rat) (CMV)

Sign In for Pricing
View Details
Transmissible Gastroenteritis Virus (TGV) (MaxLight 650) discontinued
T8265-30-ML650 100 µL

Transmissible Gastroenteritis Virus (TGV) (MaxLight 650) discontinued

Sign In for Pricing
View Details
CXorf64 Protein Lysate (Human) with C-Ha Tag
17214031 100 µg

CXorf64 Protein Lysate (Human) with C-Ha Tag

Sign In for Pricing
View Details
NG2 (4D1)
sc-47718 200 µg/mL

NG2 (4D1)

Sign In for Pricing
View Details